CREBBP and acute myeloid leukemia: Second, the lysine acetyltransferase activity of CREBBP/EP300 supports leukemogenesis in different AML genetic contexts [58, 59, 61] and its pharmacological repression altered DNA replication and repair processes, induced cell cycle arrest, apoptosis (e.g. in KMT2A-rearranged leukemia [59]) and impairment of the clonogenic growth of primary AML cells, while sparing normal hematopoietic progenitors [58].